Desperate hope: stem cells tested on one child with rare muscle disease
NCT ID NCT05154851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial gives a single child with a rare form of congenital muscular dystrophy access to their own banked stem cells. The cells are given through 14 IV infusions to see if they are safe and can help control the disease. Because it involves only one patient, the results will be very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
- What this could lead to
- If successful, this could point toward a way to slow or manage congenital muscular dystrophy in this patient.
- What could go wrong
- This is a single-patient expanded access study, not a full clinical trial. Results may not apply to others, and risks include infection or infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL MUSCULAR DYSTROPHY DUE TO LAMIN A/C MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, 77478, United States